Overview of Calperos Osteo

Quick Facts

Property	Description
Active Ingredients	Calcium Carbonate, Dihydrotachysterol
Form	Chewable tablets
Pharmacological Class	Correctors of calcium-phosphorus metabolism
Common Purpose	Addressing calcium and Vitamin D deficiency states
Origin	Mineral and synthetic Vitamin D analogue

Calperos Osteo is defined as a polycomponent pharmaceutical preparation that belongs to the pharmacological class of correctors of calcium-phosphorus metabolism, specifically formulated to address nutritional support for bone health. It functions as a fixed-dose combination product, combining an essential mineral with a synthetic vitamin derivative to ensure comprehensive support for the body's mineral balance. This preparation is often clinically recognized for its role in correcting mineral imbalances, particularly in patient groups susceptible to deficiencies.

Identity and Pharmacological Classification

Calperos Osteo is classified as a mineral and vitamin D analogue supplement designed to mitigate deficiencies in critical nutrients required for the skeleton. This preparation utilizes precise components to achieve its antihypocalcemic effect. Unlike some combinations using cholecalciferol (Vitamin D3), the inclusion of Dihydrotachysterol—a highly potent, synthetic Vitamin D analogue—provides a feature often sought when specific mineral regulation is necessary.

Composition, Form, and Origin (Calcium Carbonate and Dihydrotachysterol)

The preparation is composed of two active ingredients: Calcium Carbonate and Dihydrotachysterol. Calcium Carbonate serves as the primary source for elemental calcium supply, while Dihydrotachysterol is a calciferol derivative, which plays a crucial role in regulating calcium uptake. The product is provided as chewable tablets and is intended for oral administration. This particular dosage form is designed to enhance adherence for patient groups who may have difficulty swallowing standard tablets.

General Purpose in Mineral Homeostasis

The general purpose of Calperos Osteo is to provide critical support for maintaining mineral homeostasis, thereby addressing underlying calcium deficiency states. By combining a direct calcium source with a powerful enhancer of calcium absorption and utilization, the preparation ensures that the mineral is not only supplied but also effectively managed by the body. This dual action facilitates necessary bone mineralization and supports the metabolic processes fundamental to preserving overall skeletal integrity.

What side effects are possible with Calperos Osteo?

Possible Side Effects and Safety Information

The safety profile of Calperos Osteo, a combination of Calcium Carbonate and Dihydrotachysterol, is characterized by officially documented adverse reactions related primarily to mineral regulation, as noted in government regulatory documents. The most significant safety constraint involves the potential for elevated mineral levels in the body.

Adverse Reaction Classification

Side effects are officially classified by frequency based on regulatory standards:

Uncommon (affecting up to 1 in 100 people): Includes Hypercalcaemia (high calcium levels in the blood) and Hypercalciuria (high calcium levels in the urine). These are the key expected adverse reactions related to the medicine's function within the Metabolism and Nutrition system.
Rare (affecting up to 1 in 1,000 people): Includes Gastrointestinal disorders such as constipation, flatulence, nausea, abdominal pain, and diarrhoea, as well as Skin and subcutaneous tissue disorders like rash, pruritus (itching), and urticaria (hives).

Serious Adverse Reactions and Safety Constraints

The official labeling documents note the risk of Severe Hypercalcaemia, which, particularly with prolonged high-dose exposure, may lead to serious outcomes such as renal impairment or Milk-Alkali Syndrome. Furthermore, specific safety considerations are officially required for certain patient groups:

Renal Impairment: Requires close laboratory monitoring of serum and urinary calcium and renal function due to a heightened risk of hypercalcaemia.
Pregnancy and Lactation: Sustained hypercalcaemia must be avoided during pregnancy due to documented risks of fetal harm. The medicine is contraindicated in patients with pre-existing hypercalcaemia, severe hypercalciuria, or calcium lithiasis (kidney stones).

Overdose and Emergency Response

Overdose and when to seek help

Overdosage with Calperos Osteo is documented as leading to manifestations of systemic hypercalcemia, driven by the potent calciferol component, Dihydrotachysterol. The formally listed early symptoms of this condition include generalized weakness, headache, anorexia (loss of appetite), nausea, vomiting, abdominal cramps, constipation, vertigo, and muscle pain. As toxicity progresses, late symptoms may involve mental confusion, depression, amnesia, hallucinations, and potentially coma.

The official regulatory documentation identifies severe and potentially life-threatening outcomes. These complications include metastatic calcification of soft tissues, specifically affecting the heart, blood vessels, and kidneys, along with the development of renal insufficiency (evidenced by polyuria and increased thirst). Death is a documented risk associated with severe, untreated cardiovascular or renal failure.

When to Seek Urgent Medical Help

In the event of suspected overdose, regulatory guidance mandates the immediate withdrawal of the medicine. Urgent medical help must be sought immediately if a state of hypercalcemic crisis is suspected; this is a severe condition requiring vigorous treatment. Management is symptomatic and supportive, focusing on physiological reversal through hydration (often with intravenous saline) and the use of diuretics. Treatment protocols must be controlled by regular determinations of blood calcium levels, as no specific chemical antidote is known.

Therapeutic Uses of Calperos Osteo

What Calperos Osteo Treats: Main Uses and Benefits

Calperos Osteo is a combined supplement of Calcium and Vitamin D3 generally used to address two main therapeutic domains, providing essential support for bone health and mineral balance. The primary uses involve addressing deficiencies and providing supportive management for osteoporosis. This combination is an appropriate adjunct to specific osteoporosis treatment and is applied across domains where additional symptomatic support is needed.

Therapeutic Domains and Patient Benefit

This medicine is relevant for conditions characterized by periods of heightened symptoms related to systemic imbalance or physical discomfort. It is often used when low mineral levels create noticeable interference with daily comfort. This application helps ease the overall symptom burden.

Quick Fact: Support for Functional Strain

Condition Categories

The supplement is considered relevant in conditions involving episodic or fluctuating manifestations where symptoms may intensify temporarily. It is relevant in contexts marked by increased discomfort or tension, such as:

Supportive Management of Osteoporosis (as an adjunct therapy).
Addressing Calcium and Vitamin D Deficiencies.

Eligibility and Restrictions for Use

Eligibility Profile: Official Regulatory Information

This medicine is primarily intended for adults with documented Calcium and/or Vitamin D Deficiency States and for use as adjunct therapy for Osteoporosis. Official regulatory documents establish strict non-eligibility based on metabolic status and organ function.

Contraindicated Populations

Calperos Osteo must not be used by patients who have pre-existing conditions that already involve excess calcium or Vitamin D. This includes individuals with Hypercalcaemia (high blood calcium levels) or Hypervitaminosis D (Vitamin D overdosage). Contraindication also applies to patients with Severe Renal Impairment, Hypercalciuria, or those with Nephrolithiasis (kidney stones).

Age and Physiological Limitations

Use is typically not recommended for pediatric populations below a certain age, as clinical data is often not established. For Reproductive Status, the medicine is absolutely contraindicated in breastfeeding mothers due to the risk of transferring the active substance to the infant. Use during pregnancy is restricted and only permitted when benefits strictly outweigh potential risks.

Condition-Specific Restrictions

Eligibility is conditional for patients with pre-existing Impaired Renal Function (excluding severe failure) or conditions like Sarcoidosis. These groups must use the medicine only under controlled conditions and with frequent medical monitoring.

What should I know about interactions with other medicines?

Interactions Affecting Systemic Exposure

The calcium component of Calperos Osteo causes a documented pharmacokinetic interaction by binding to or chelating certain co-administered medications within the digestive tract. This binding significantly reduces the systemic absorption of the co-administered drug, an effect known to occur with specific antibiotics, including Tetracyclines and Quinolones. To maintain adequate therapeutic exposure, regulatory documents mandate separation of the administration time for these antibiotics, as well as for Bisphosphonates and oral Iron Supplements. Furthermore, certain Anticonvulsants, such as Phenytoin, are officially documented to increase the catabolism of the Dihydrotachysterol component, potentially altering its therapeutic levels.

Interactions Affecting Calcium Balance

Co-administration with other Vitamin D analogues is restricted, as regulatory information documents an additive pharmacodynamic effect leading to an unacceptable risk of hypercalcemia and toxicity. This hypercalcemia risk is also documented when the product is combined with Thiazide Diuretics, which reduce the renal excretion of calcium. For patients using Cardiac Glycosides, the potential for hypercalcemia creates a serious documented risk of potentiating the glycoside's effect, which can lead to the exacerbation of ventricular arrhythmias. Specific population notes indicate that monitoring is especially relevant in elderly patients and those on diuretics.

Non-Medicinal Interactions

Specific foods high in oxalic acid (e.g., spinach, rhubarb) or phytic acid (e.g., bran) are documented to interfere with calcium absorption. The official prescribing information also notes that the consumption of grapefruit or grapefruit juice may alter the blood concentrations of the Dihydrotachysterol component.

Mechanism of Action

Enhancing Mineral Absorption via Nuclear Receptor Agonism

The mechanism centers on Dihydrotachysterol, which acts as an agonist at the nuclear Vitamin D Receptor (VDR). VDR activation initiates a genomic cascade that upregulates the synthesis of calcium-binding proteins and transporters within the intestinal cells. This molecular action increases the activity of the biological machinery responsible for extracting the essential mineral from the digestive tract and into the systemic circulation.

Substrate and Regulator Synergy for Stable Balance

The mechanism relies on the synergy between the two components: Calcium Carbonate provides the necessary elemental substrate, while the VDR agonism acts as the regulator of the uptake process. This dual action increases the net systemic calcium balance by ensuring that a high mineral supply meets a high capacity for absorption, contributing to mineral delivery to bone and other tissues.

Consistent Action via Metabolic Pathway Bypass

Dihydrotachysterol is metabolically distinct as it requires only a single, hepatic hydroxylation step for activation, bypassing the more complex, tightly regulated renal step required by natural Vitamin D. This structural feature provides a consistent and sustained supply of the active compound to the VDR, reducing dependence on the variable activity of the renal enzyme system and promoting sustained regulation of calcium homeostasis.

Dosage and Administration Information

How to Use Calperos Osteo: Official Administration Guidelines

This section describes the high-level, standardized usage patterns for Calperos Osteo regarding its composition of Calcium Carbonate (1000 mg elemental calcium) and Cholecalciferol (Vitamin D3, 880 IU).

Administration Route and Standard Dosing

Calperos Osteo is approved for the oral route of administration and is supplied as chewable or suckable tablets. The standard dosing regimen for adults and older adults is one tablet taken once daily. This dose provides 1000 mg of elemental calcium and 880 International Units (IU) of Vitamin D3 and is typically part of a long-term treatment plan for chronic deficiency states or as an adjunct to osteoporosis therapy.

Procedural Instructions and Timing

To ensure proper use, the tablet must be chewed or sucked before swallowing, rather than being ingested whole. The medicine can be taken at any time of day and is independent of meals.

However, proper administration requires maintaining a time interval when consuming certain foods or medications. For instance, the intake should be separated from products containing oxalic acid (found in spinach and rhubarb) or phytic acid (found in whole-grain products). Specific oral medications, such as tetracycline antibiotics or bisphosphonates, also necessitate time separation for optimal absorption.

Population-Specific Use

Official labeling includes a specific modification for use during pregnancy, where the daily dose, if deemed necessary, must not exceed half a tablet, which corresponds to 500 mg elemental calcium and 440 IU Vitamin D3.

Recent Clinical Evidence

Research evidence / Overview of studies for Calperos Osteo

This overview describes the types of clinical studies and research available for the combination of calcium carbonate and a vitamin D analogue, focusing only on the structure of the evidence and what research has examined, without offering clinical guidance.

Evidence for Addressing Calcium and Vitamin D Deficiency States

Research has primarily examined the use of calcium and vitamin D combinations in individuals with identified low mineral status. The research base includes Randomized Controlled Trials (RCTs) and meta-analyses, which examined the combination against a control or placebo.

In these studies, research examined changes in biochemical markers—the substances in the blood that reflect the body's mineral balance. The key outcomes monitored included serum levels of 25-hydroxyvitamin D [25(OH)D], which measures vitamin D status, along with calcium and Parathyroid Hormone (PTH) concentrations. Studies monitored these outcomes in adults and older adults identified as having deficiency or insufficient mineral levels.

Evidence for Use as Adjunct in Osteoporosis Management

Research examined this combination in individuals concurrently receiving specific anti-osteoporosis prescription therapies. The evidence landscape includes large-scale, long-term RCTs and systematic reviews that focused on skeletal health outcomes.

The outcomes monitored in these trials were primarily clinical endpoints that require multi-year observation, such as the frequency of total, non-vertebral, and hip fractures. Research also examined intermediate measures, including assessing changes in Bone Mineral Density (BMD) at skeletal sites like the lumbar spine. Studies primarily focused on older adults, particularly postmenopausal women, who were concurrently receiving other osteoporosis treatments.

Key Research Gaps and Areas of Uncertainty

The primary evidence base for long-term clinical outcomes, especially those related to fracture risk, largely derives from studies that utilized Cholecalciferol (Vitamin D3). Research is less extensive regarding the specific long-term impact of the synthetic analogue, Dihydrotachysterol, which is included in Calperos Osteo. Research highlights variability across studies, and data show patterns related to fracture incidence that are not entirely consistent across all conducted meta-analyses.

Frequently Asked Questions (FAQ)

Common questions about Calperos Osteo (FAQ)

Q: Is it common to have mild stomach upset when starting Calperos Osteo?

Officially documented gastrointestinal upsets, such as feelings of nausea, flatulence, or stomach pain, are classified as rare side effects. This means they are expected to affect only up to 1 in 1,000 people. This information is based on the official safety profile for the medicine.

Q: Does Calperos Osteo interfere with antibiotics?

Official labeling documents state that the calcium component can interfere with the body's absorption of certain antibiotics, specifically tetracycline and quinolone antibiotics. Because of this, the official guidance is to separate the time of administration of Calperos Osteo from these particular medicines.

Q: Does Calperos Osteo affect the absorption of iron supplements?

Official documents advise that the administration must be separated from oral iron supplements. This is because the calcium component can bind to the iron in the digestive tract, which potentially reduces the amount of iron the body absorbs.

Q: What happens if I stop taking Calperos Osteo?

This medicine is often prescribed as a long-term treatment to address chronic mineral deficiency states. Based on official information, if use is discontinued, it may result in the body's mineral levels returning to an insufficient status over time.

Q: What is the typical duration of treatment with Calperos Osteo?

According to the official administration guidelines, this medicine is typically part of a long-term treatment plan. It is often used for chronic deficiency states or as maintenance therapy when prescribed alongside other treatments for osteoporosis.

Q: Are there certain foods or drinks that should be avoided while using Calperos Osteo?

Official documents advise on maintaining a time interval when consuming certain foods that are high in oxalic acid (found in spinach and rhubarb) or phytic acid (found in whole-grain products). These substances can interfere with calcium absorption. Consumption of grapefruit is also noted as potentially altering the blood concentrations of one of the active components.

Q: Is Calperos Osteo suitable for vegetarians or vegans?

The active components are a mineral and a synthetic compound. However, official labeling for some chewable tablets of this type indicates the use of certain excipients. This is a factor described in official documents that patients following vegetarian or vegan diets may wish to note.

Q: What is the role of the counter-ion (e.g., carbonate, citrate) of calcium in Calperos Osteo?

The counter-ion used in this medicine is carbonate, which forms the compound Calcium Carbonate. Its official role is to serve as the primary elemental substrate that provides the mineral content needed by the body.

Q: Can someone with diabetes safely use Calperos Osteo?

Official labeling does not list diabetes as a contraindication for using the medicine. However, because this is a chewable tablet, the excipients may include certain sugars like sucrose or sorbitol, which is a general consideration noted in official patient information.

Q: What is the main difference between Calperos Osteo and just a regular calcium supplement?

The main difference is the inclusion of the synthetic component, Dihydrotachysterol. This component is described in the official mechanism information as requiring only a single liver activation step. This is intended to promote a consistent and sustained supply of the active compound to regulate the body's calcium uptake.

Q: Is Calperos Osteo the same as Calperos 500 or Calperos 1000?

Official information indicates that Calperos Osteo is a fixed-dose combination containing both Calcium Carbonate and the synthetic Vitamin D analogue Dihydrotachysterol. Products labeled Calperos 500 or Calperos 1000 typically contain Calcium Carbonate only as the active ingredient.

Q: What are the non-active ingredients listed in Calperos Osteo?

Official regulatory information lists the non-active ingredients (also called excipients) in the product’s Summary of Product Characteristics (SmPC) or package leaflet. These ingredients typically include sweeteners such as sorbitol and various flavorings used in the chewable tablet form.

Q: Do studies support the use of Calperos Osteo for fracture prevention?

Official research overviews confirm that studies have examined fracture outcomes for similar calcium and vitamin D combinations. However, research indicates that the evidence base is less extensive regarding the specific impact of the synthetic analogue, Dihydrotachysterol.

Q: Can children or adolescents use Calperos Osteo?

Official regulatory documents state that use is typically not recommended for pediatric populations (children and adolescents) below a certain age. This is because specific clinical data for this age group is often not established for the combination product.

Q: Is it possible for Calperos Osteo to cause kidney stones?

The medicine is contraindicated (must not be used) in patients with pre-existing kidney stones. An officially documented uncommon side effect is Hypercalciuria (high calcium levels in the urine), which is a factor associated with the potential for calcium-based stone formation.

Q: Why is this specific combination of ingredients in Calperos Osteo used for bones?

Official information describes the use of this combination as relying on the synergy of the two components. Calcium Carbonate provides the necessary elemental mineral substrate, while the synthetic analogue Dihydrotachysterol acts as a regulator to promote efficient uptake and management of the mineral for bone health.

Q: Are there different strengths or dosages of Calperos Osteo available?

Official administration guidelines describe the standard dosage as one tablet taken once daily. The only deviation from this strength noted in official labeling is the restriction to no more than half a tablet for use during pregnancy.

Q: Is the calcium source in Calperos Osteo natural or synthetic?

Official product information describes the Calcium Carbonate component as being of mineral origin. The Dihydrotachysterol component is defined as a synthetic Vitamin D analogue.

Q: Does Calperos Osteo have an impact on dental health?

Some non-active ingredients (excipients) used in chewable tablets, such as sucrose, are officially noted as potentially being harmful to teeth if the medicine is taken chronically over a long period of time.

Q: Is a medical check-up needed before starting Calperos Osteo?

Official labeling requires that certain patient groups, such as those with impaired renal function or conditions like sarcoidosis, use the medicine only under controlled conditions and with frequent medical monitoring. Official documents describing these monitoring requirements may suggest a prior medical evaluation is necessary to establish eligibility.

Q: What is the shelf life of Calperos Osteo tablets?

Official product information specifies a shelf life for the sealed product. Instructions state that the product must not be used after the expiry date printed on the packaging.

Q: Is there a maximum amount of time someone is described as safely using Calperos Osteo?

Official prescribing information describes the product as typically part of a long-term treatment plan for chronic deficiency states. The labeling does not note a specific maximum duration of use.

Q: Do I need to change my diet while taking Calperos Osteo?

Official materials advise on maintaining a time interval when consuming certain foods high in oxalic acid or phytic acid, as they can interfere with calcium absorption. This separation is necessary, which patients may manage by adjusting their eating habits.

Q: Why is it described that Calperos Osteo should not be taken with phosphate-containing products?

This restriction is described because the active components regulate the balance of both calcium and phosphate in the body. Combining this medicine with other phosphate-containing products may lead to additive effects, increasing the risk of Hyperphosphatemia (high phosphate levels), which is an undesirable mineral imbalance.

Q: Are there any specific medical tests recommended while using Calperos Osteo?

Official safety constraints require close laboratory monitoring of serum and urinary calcium and renal function for specific patient groups. This is mandated for patients with pre-existing renal impairment due to a heightened risk of hypercalcaemia.

How should Calperos Osteo be stored and disposed of?

How to Store and Dispose of Calperos Osteo

The storage and disposal requirements for Calperos Osteo are defined by official regulatory labeling to ensure product stability and environmental safety.

Requirement Area	Official Instructions
Storage Temperature	Do not store above 25 C.
Protection	Keep protected from moisture.
Child Safety	Keep the medicine out of the sight and reach of children.
Stability	Do not use after the expiry date printed on the packaging.
Disposal	Do not dispose of medicine via wastewater or household waste.

For proper disposal of unused or expired tablets, you must consult your pharmacist. This ensures that the product is discarded according to local environmental regulations and does not contaminate water sources.

Calperos Osteo